148672-74-6Relevant articles and documents
Design and synthesis of 3,3-piperidine hydroxamate analogs as selective TACE inhibitors
Lombart, Henry-Georges,Feyfant, Eric,Joseph-McCarthy, Diane,Huang, Adrian,Lovering, Frank,Sun, LinHong,Zhu, Yi,Zeng, Congmei,Zhang, Yuhua,Levin, Jeremy
, p. 4333 - 4337 (2007)
Structure-based methods were used to design β-sulfone 3,3-piperidine hydroxamates as TACE inhibitors with the aim of improving selectivity for TACE versus MMP-13. Several compounds in this series were synthesized and evaluated in enzymatic and cell-based
PYRAZOLOPYRIDAZINE DERIVATIVES, PREPARATION METHOD THEREOF AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME
-
Paragraph 0245-0249, (2020/11/14)
The present invention is a pyrazolopyridazine derivative. A pharmaceutical composition for preventing or treating cancer contains the pyrazolopyridazin derivative compound Hsp90 according to the present invention as an active ingredient, which can be used as Hsp90 a pharmaceutical composition for preventing or treating Hsp90-related diseases such as melanoma, brain tumor, breast cancer, lung cancer and the like. (by machine translation)
PHARMACEUTICAL COMPOUNDS
-
Paragraph 0793; 0794; 0795; 0796, (2018/04/26)
This invention relates to compounds that are agonists of the muscarinic M1 receptor or M1 and M4 receptors and which are useful in the treatment of muscarinic M1 or M1/M4 receptor mediated